BEIJING, Sept. 18, 2024 /PRNewswire/ — A team of representatives from multiple well-known overseas media outlets visited Shendong Coal Group under CHN Energy Investment Group in northwest China on September 14.

During the visit, the foreign media representatives applauded Shendong Coal’s practice and innovation in smart and green development, praising the company as "a pacesetter in smart green development" in the global coal industry.

Shendong Coal now has 13 modern, safe, and efficient mines. It has established China’s first coalmine with a single capacity of 200 million tons and formed coalmine clusters at a scale of ten million tons.

Gao Huiwu, an senior executive of Shendong Coal, gave an introduction of the company’s "0587" intelligent coal mine development goals and its achievements in unmanned operation. The application of intelligent mines has not only improved production efficiency, but also helped to ensure safety.

Isaura Diez Millan, a journalist from Latin American News Agency said that this company has totally changed her previous perception of Chinese coalmines as dangerous places.

Real-time production data of coalmines is displayed on the electronic screen of the intelligent control center of Daliuta Coalmine, while two high-tech space capsule seats have particularly drawn visitors’ attention. The level of intelligence in Shendong Coal is impressive, said Jose Luis Barcelo Mezquita, president of Financial World, a Spanish financial media group.

The Halagou coal mining subsidence area in Daliuta town used to a desert area, but has now been transformed by Shendong Coal into an ecological demonstration areas through comprehensive restoration, and established a development mode featuring sea buckthorn economic forests planting and industrial production. The staff from Shendong coal briefed foreign media representatives on the company’s ecological management model.

"This model strikes a balance between economic gains and ecological benefits, making it a role model for companies from across the world," commented Naveed Hussain, editor-in-chief of Express Tribune in Pakistan.

Romania also boasts abundant coal reserves, yet it is undergoing an energy transition, too. The smart and green development practices of Shendong Coal serve as a reference for the transformation and upgrading of the global coal industry, said Stefan Radeanu, editorial director of Curierul National in Romania. 

Original link: https://en.imsilkroad.com/p/342156.html

Source : Xinhua Silk Road: Foreign media team lauds "green miracle" created by Shendong Coal in NW. China

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SAN DIEGO, Sept. 18, 2024 /PRNewswire/ — Hyundai Bioscience USA announced that it has signed an MOU with the University of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean headquarters, in treating "Long-COVID". The trial will be led by UCSD Professor Ajay Bharti, an infectious disease specialist and clinical trialist. Dr. Bharti’s particular expertise in the neurocognitive effects of viral illnesses make him perfectly suited to run the investigator initiated trial.

"This is an outstanding opportunity for UC San Diego and Hyundai Bioscience to partner together to tackle Long-COVID," Professor. Davey Smith, Director of the UCSD Altman Clinical and Translational Research Institute (ACTRI) of UCSD and an authority on viral illnesses, especially COVID, said about the collaboration. "There is no therapy currently available for the condition, which affects millions of people around the world."

Xafty, an oral antiviral agent, is a new drug that improved the bioavailability of niclosamide, which is known to have antiviral efficacy against more than 30 viruses. It is currently in a phase 3 clinical trial in Korea targeting high-risk groups for COVID-19 and is expected to apply for phase 3 to the U.S. FDA soon. In a previous phase 2 clinical trial, Xafty successfully met the FDA’s primary endpoints, demonstrating a faster symptom improvement rate than other existing treatments, especially in high-risk groups.

"Being able to reduce symptoms during acute COVID-19 is an impressive accomplishment," Dr. Smith, who has helped run numerous antiviral trials in COVID-19, HIV, and Mpox, said. "Many large recent trials testing antivirals have not had such success. This may point to Xafty’s effectiveness in Long-COVID as well."

Long-COVID is a complex disease that is suggested to be caused by residual virus, excessive inflammation, and consequent nerve damage. Patients suffer from various symptoms such as chronic fatigue, inflammation, and cognitive decline, but existing treatments rely on a single mechanism and fail to resolve these complex symptoms. This is one of the reasons why a clear treatment for Long-COVID has not yet been developed.

Xafty is expected to resolve the complex symptoms of Long-COVID through inflammation inhibition and neuro-protection mechanisms, rather than simply suppressing the virus. It is because niclosamide, Xafty’s main pharmaceutical ingredient, is anticipated to provide practical therapeutic effects to patients through multiple mechanisms such as virus removal, suppression of immune hypersensitivity, and recovery of nerve damage.

In a recent Parkinson’s disease preclinical study conducted by Hyundai Bioscience, Xafty demonstrated to promote dopamine production and nerve cell recovery. When Xafty was administered to a Parkinson’s animal model with suppressed dopamine production, a higher dopamine level was confirmed than in the group administered with the existing Parkinson’s disease treatment, dopamine precursor (Madopar®), suggesting that it can make a significant contribution to improving symptoms such as brain fog and cognitive impairment due to nerve damage in people with Long-COVID.

Dr. Ajay Bharti, the PI of this study, said, "We already knew about the broad-spectrum antiviral efficacy of niclosamide, but after seeing data showing that Xafty, having improved the long-standing problem of bioavailability, showed excellent symptom improvement in a COVID-19 clinical trial, especially in the high-risk group, we came up with the idea of using the drug to treat Long COVID." He added, "In particular, the fact that Xafty recovered neurons in a preclinical study of Parkinson’s disease and promoted dopamine production, resulting in higher dopamine levels than the control group that took Madopar®, was an important trigger for this clinical study."

Dr. Smith added, "The goal of this study is to confirm that niclosamide can solve the complex symptoms of Long COVID through multiple mechanisms such as virus suppression, inflammation suppression, and neuroprotection. We hope that the clinical trial will be successful and provide a practical treatment option for Long COVID patients, which will be historic."

About Hyundai Bioscience

Hyundai Bioscience is a biotechnology company that develops drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea.

For more information, please contact Ms. Joobin Jung, Global PR Manager ([email protected]).

Source : Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BEIJING, Sept. 18, 2024 /PRNewswire/ — XCHG Limited (XCHARGE) (NASDAQ: XCH) announced the pricing of its initial public offering.

XCharge, founded in 2015, is a global leader in integrated EV charging solutions, focusing on Innovative New Energy Technologies and Sustainable Development . The Company offers comprehensive EV charging solutions which primarily include the DC fast chargers, the advanced battery-integrated DC fast chargers, as well as its accompanying services, assisting the rapid development of the new energy industry. 

XCharge has developed one of the world’s first two-way energy storage charging piles – the Net Zero Series DC high-power charging energy storage equipment, which has been commercialized in Europe, North America and Asia, and customers are from EV manufacturers, global energy companies and charging pile operators. According to Frost & Sullivan, XCharge is one of Europe’s leading suppliers of high-power charging solutions in terms of sales volume in 2023.

Aatish Patel, President and Co-founder of XCharge North America, said: "Our mission is far more than building EV charging piles, but to enable everyone to enjoy the convenient, fair and practical sustainable energy. Now for XCharge, IPO is a milestone, and in the future, XCharge will continue to provide global optimization solutions based on the infrastructure and to develop products for specific markets to provide net zero and affordable solutions worldwide, so that everyone can participate in and jointly build a more resilient and sustainable future!"

Dr. Bo Bai, Chairman and Founder of Asia Green Fund, said: "Congratulations to XCharge’s IPO. As a shareholder of XCharge, Asia Green Fund is very honored to have participated in and witnessed its growth. We share the same vision of low carbon and sustainable development. The follow-up will be more anticipated that the company expand its influence globally and highlight its greater value on promoting Net Zero future. 

Source : XCharge, Asia Green Fund's Portfolio, Successfully Listed on Nasdaq

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE, Sept. 18, 2024 /PRNewswire/ — MediSun Energy, a leader in pioneering osmotic (blue) energy technology, is thrilled to announce the signing of a Memorandum of Understanding (MoU) with Emirates Electrical and Instrumentation Company (EEIC), a Ghobash Group Enterprise. This strategic collaboration appoints EEIC as the exclusive distributor of MediSun’s WEGen technologies across the United Arab Emirates (UAE).

Dusun Kim (left), Hagop Dermosessian (right)

MediSun’s WEGen technology offers cutting-edge solutions to address the UAE’s pressing energy and environmental needs. Utilizing Reverse Electrodialysis (RED) technology, WEGen efficiently converts saltwater into electricity, significantly enhancing energy efficiency. This innovative approach not only produces clean energy but also reduces overall energy consumption, aligning with the UAE’s long-term sustainability goals.

Additionally, WEGen technology incorporates Carbon Capture, Utilization, and Storage (CCUS) and zero brine production, effectively capturing carbon emissions and eliminating harmful brine waste. This contributes to achieving net-zero carbon emissions, further supporting the UAE’s commitment to environmental sustainability. MediSun’s dedication to clean energy innovation is helping the region move closer to its sustainability targets.

Dusun Kim, CEO of MediSun Energy, stated: "Collaborating with EEIC marks a pivotal moment for MediSun Energy. Their extensive experience and robust market presence in the UAE will be instrumental in advancing our mission to provide cutting-edge and sustainable energy solutions. We are excited about the opportunities this collaboration will create."

Hagop Dermosessian, General Manager, at Emirates Electrical & Instrumentation Company (EEIC) & GCG Engineering Services, added: "Our collaborative efforts will help to stimulate the future of sustainable water brine management in the UAE. Leveraging our core competencies to deliver innovative and efficient solutions is an exciting step to protect the wider environment and mitigate the effects of costly RO systems. Our collaboration with MediSun Energy as their exclusive distributor for the UAE and our expertise spanning over 2 decades reflect our dedication to delivering comprehensive solutions in the renewable energy field."

Together, EEIC and MediSun Energy are positioned to lead the transformation of water security in the UAE, demonstrating a shared commitment to environmental stewardship and technological advancement.

About MediSun Energy

MediSun Energy is a technology-driven company dedicated to advancing clean and efficient energy solutions. Our innovative WEGen technology utilises osmotic power to enhance energy efficiency in water desalination and to generate renewable energy. Committed to a net-carbon neutral future, we strive to deliver practical, sustainable solutions that align with our vision of a world powered by clean and green energy.

About EEIC

Established in 2002, Emirates Electrical & Instrumentation Company (EEIC) – A Ghobash Group Enterprise, takes pride in being a leading Engineering, Procurement and Construction (EPC) Company in the UAE, With over 500 specialists and cutting-edge technology, EEIC excels in mechanical, electrical, instrumentation and control systems, undertaking complex projects across various sectors such as Oil & gas, Energy, Power, Utilities, Water Treatment & Management, and Smart Infrastructure. EEIC’s clients include ADNOC, government entities, semi-government organizations, and leading EPC contractors. The company is focused on renewable sustainable energy solutions, aiming to be a top contractor and employer in its industry.

For more information, visit www.medisun.energy or write to [email protected]. You can also follow MediSun Energy on LinkedIn.

Source : MediSun Energy Teams Up with EEIC to Strengthen UAE's Water Security and Advance Sustainable Energy Solutions

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Debut of Asia’s Premier Drone Trade Event Leads with Renown Industry Players

BANGKOK, Sept. 18, 2024 /PRNewswire/ — DronTech Asia 2024, the international exhibition and conference in Thailand dedicated to drones and their technology, proudly announces several leading drone manufacturing and solution providing companies’ participation. The inaugural event welcomes expanded product depth and learning from across Asia including China, Singapore, Malaysia, and of course Thailand to bring more knowledge, innovations, and updates for the industry. DronTech Asia 2024 will take place 25-27 November at IMPACT Exhibition and Convention Center in Muang Thong Thani, Thailand.

From UAV (unmanned aerial vehicle) to UGV (unmanned ground vehicle) to USV and UUV (unmanned surface vehicles & unmanned underwater vehicles), DronTech Asia provides the rapidly growing global drone industry in Asia with a forum for business exchange, technological innovation sharing, and policy & regulation furtherment. Latest confirmed companies to showcase at DronTech Asia 2024 include:

CUAV Tech Inc., Ltd (China) – one of the largest open-source flight controller suppliers in China and a partner of PX4 and Ardupilot Grepow Battery Co., Ltd. (China) –one of the largest LiPo battery manufacturers globally, catering to a wide range of industries, including drones, UAVs, electric vehicles, medical devices, and more. Hobbywing Technology Co., Ltd. (China) – leader of high-power density brushless power systems for drones and RC models R V Connex Co., Ltd. (Thailand) – specialist in advanced UAV and drone technology, manufacturing, system design, and integration ST Engineering Aerospace Ltd. Brand DroNet (Singapore) – solution providers of DrN series drones and drone ports to provide complete unmanned drone operations SYSTRONICS CO., LTD (Thailand) – leader in digital technology for over 22 years, specializing in drone enterprise solutions, drone delivery, and VTOL drones. NAC Drone (Thailand) – specializing in developing innovative agriculture drones and UAV technology for the energy sector Benelli Defense (Italy) – specializes in versatile, multipurpose combat shotguns designed for anti-drone operations.

These companies join the ranks of SISD (Thailand) Co., Ltd.), Thai Sky Vision Co., Ltd., J.S.T. SERVICES CO.,LTD., SwissDrones, SKYVIV, Icreativesystems, and more. 

DronTech Asia 2024 Exhibitors: CUAV Tech, Grepow Battery, Hobbywing Technology, R V Connex

DronTech Asia 2024 Exhibitors: ST Engineering, SYSTRONICS, Hobbywing NAC Drone, Benelli Defense

Drone technologies today have immense impact across vertical markets including agriculture & forestry, defense & security, transportation, infrastructure, and entertainment. 

More than an exhibition, DronTech Asia 2024 will play host to an international conference covering the newest in drone application developments. Through DronTech Asia’s seminars, live demonstrations, and technical presentations, emerging and urgent topics related to drones including drone deployment & management, cybersecurity, AI, and end-user education & training will take shape. 

Committed to advancing the industry and its stakeholders, DronTech Asia is proudly supported by the Civil Aviation Authority of Thailand (CAAT), the Digital Economy Promotion Agency (Depa), the Defence Technology Institute, Thailand Convention and Exhibition Bureau, and the Drone Association of Thailand. To learn more about DronTech Asia and to pre-register visit DronTechAsia.com. 

For remaining exhibiting and sponsorship opportunities contact: [email protected].

For media inquiries please contact: [email protected]

Source : DRONTECH ASIA 2024 WELCOMES INTERNATIONAL DRONE PLAYERS CUAV TECH INC., R V CONNEX CO., LTD., ST ENGINEERING AEROSPACE LTD. AND MANY MORE

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Epitomee’s Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise.

CAESAREA, Israel, Sept. 17, 2024 /PRNewswire/ — Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially cleared the Epitomee® Capsule, a cutting-edge ingestible medical device designed to support weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m² alongside diet and exercise. This novel, drug-free treatment provides a new option for millions of health-conscious individuals in the U.S.

FDA Clears Epitomee® Capsule for Weight Management! The FDA has officially cleared the Epitomee® Capsule, a groundbreaking oral prescription device designed to support weight management in overweight and obese adults with a BMI of 25–40 kg/m² alongside diet and exercise. This innovative, drug-free solution works by promoting a feeling of fullness, empowering a healthier lifestyle.

The Epitomee® Capsule represents an innovative prescription option in weight management solutions, offering a drug-free alternative that differs from injectable treatments. With FDA clearance extending to adults with a BMI starting at 25, Epitomee® Capsule is accessible to a broader range of patients looking for tolerable and easy to use weight management solutions. The Epitomee® device is encased in a standard size, self-administered ingestible capsule. Once the Epitomee® Capsule is swallowed, and reaches the stomach it absorbs water in the stomach and creates a three-dimensional matrix designed to occupy volume in the stomach creating a sensation of fullness, enabling weight loss. The Epitomee® Capsule mechanism of action is purely mechanical and does not involve any chemical activity. The capsule works directly in the gastrointestinal (GI) tract.

Epitomee® Capsule was cleared by the U.S. FDA following the RESET study: A prospective, randomized, double-blind, placebo-controlled, multi-canter trial. The study enrolled 279 overweight and obese adults with and without prediabetes. All 9 sites enrolled in the study were in the US, located across 9 different states. Eligible subjects were randomized to test or placebo arms. Subjects were to take one capsule of the investigational device or placebo twice daily , alongside diet and exercise, for a period of 24 weeks. The study demonstrated that both co-primary endpoints were successfully met. The RESET study demonstrated significantly better weight loss among the device group compared to the control group (P<0.0001). The co-primary endpoint of treatment responders was also achieved: the rate of Epitomee treatment group subjects whose total body weight was reduced by at least 5% at 24-weeks post randomization was 55.5% (CI; 46.1-64.6), significantly exceeding the threshold of >35% (P<0.0001).

The study demonstrated a favourable safety profile of Epitomee® treatment throughout the study duration. Epitomee® treatment was well tolerated, with fewer patient dropouts in Epitomee® group than the control group. There were no serious adverse device effects (SADEs) in the study. In addition, subjects treated with Epitomee® showed better improvement in quality of life in several items of the IWQOL-Lite-CT questionnaire.

The company also performed an additional study in 3 out of the 9 sites that participated in the RESET study, the ELECT study. In this study subjects from both the device group and the placebo group kept on taking the Epitomee® capsule for an additional 24 week period. The study demonstrated a favourable safety profile of Epitomee® treatment throughout the 48 weeks of the study duration for subjects in the device group.

Shimon Eckhouse PhD co-founder and chairman of the board, commented on the approval: "The FDA clearance of the Epitomee® Capsule marks a significant milestone in the field of weight management. Its innovative approach offers a safe and effective option for patients. The ability to manage weight through a simple, drug free capsule opens up new possibilities for those seeking to improve their health and quality of life."

Dan Hashimshony PhD, CEO of Epitomee Medical Ltd., commented: "We are proud to have received FDA clearance for our Epitomee® weight management Oral, Drug-Free solution. This achievement is the result of the innovative approach we have taken to tackle the global obesity epidemic. Our capsule offers a safe, effective, and drug-free solution to the many millions of individuals struggling with weight management. As we move forward, we are eager to bring this groundbreaking product to the U.S. market and seek strategic partnerships to fully realize its commercial potential."

About Epitomee Medical Ltd.
Epitomee Medical Ltd, a public company (TASE: EPIT), co-founded in 2005 by Shimon Eckhouse, PhD and led by CEO Dan Hashimshony PhD.  Shimon co-founded Syneron Medical Ltd. (Nasdaq: ELOS), Lumenis (formally ESC Medical) and co-founded Ventor Medical Technologies, which was acquired by Medtronic. Dan was the founding CEO of Dune Medical Devices, a surgical oncology company (acquired by Dilon Technologies). Prior to that, Dan was with X-Technologies (acquired by Guidant in 2003) and Sela Semiconductor (acquired by Camtek).

The company is a pioneering health solutions company, committed to advancing innovative therapies. With focus on safety, efficacy, and improving quality of life, Epitomee Medical strives to be at the forefront of transformative healthcare solutions.
The company is advancing two major fields: weight management and biologic drug delivery. In addition to its flagship weight management solution, Epitomee Medical is developing a cutting-edge platform focused on the oral delivery of biologics. This innovative platform is designed to transport drugs to the absorption site with enhanced bioavailability.

For more information about Epitomee Medical Ltd., please visit Epitomee Medical (https://epitomeemedical.com/)

For partnership inquiries and more information about the Weight-management capsule – contact:
Mr. Alon Heth
VP Sales and Marketing
[email protected]

Source : Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Esteemed guest Poh Chi Chuan, Executive Director (Exhibitions & Conferences) at Singapore Tourism Board, high-profile private companies and government agencies to be in attendance at the award-winning event Leaders from AI Singapore, IMDA, NVIDIA, OpenAI, and the United Nations among prominent speakers facilitating critical discussions around cutting-edge technology Amazon Web Services, Meta, Microsoft, TikTok Shop, and more are set to participate in the co-located events

SINGAPORE, Sept. 18, 2024 /PRNewswire/ — CloserStill Media, a global producer of market-leading events, today unveiled the key theme and notable attendees for Tech Week Singapore 2024.

In its 10th edition, Tech Week Singapore will focus on artificial intelligence (AI) and transformative technologies, convening the world’s most influential tech innovators and industry leaders to explore the future of digital transformation across Asia.

Celebrating a decade of meaningful connections, Gareth Bowhill, CEO at CloserStill Media, will be the event’s guest of honour. High-profile private companies and government agencies will also be in attendance, including but not limited to ambassadors from the Australian High Commission, British High Commission, Embassy of Sweden, and Embassy of Ukraine.

The premier event will also feature an impressive roster of over 600 regional and international speakers from leading organisations such as AI Singapore, Google, IMDA, NVIDIA, OpenAI, and United Nations. From insightful keynotes to panel sessions and special conference theatres, the event will unravel critical topics that resonate with leading businesses and industry leaders across Asia.

This year, Tech Week Singapore will spotlight AI as a central theme, exploring its transformative impact across industries. Beyond discussing the power of AI in today’s digital world, a series of keynote sessions and panel discussions will dive deep into various aspects that will be essential in ensuring its sustainable development in the midst of widespread adoption.

"AI can be a truly transformative technology, with the potential to drive faster economic growth, improve healthcare and education, inspire new scientific discoveries, and open up new horizons for creativity. Partnerships with both public and private sectors are critical to ensuring AI’s safe development and broad benefit distribution," said Sandy Kunvatanagarn, Head of Policy, APAC, OpenAI.

Cloud Expo Asia, DevOps Live!, Cyber Security World, Big Data & AI World, Data Centre World, eCommerce Expo, and Technology for Marketing are among the co-located shows at Tech Week Singapore set to feature their own unique elements. In addition to sharing sessions by industry giants, attendees can look forward to interactive workshops by Google Cloud at the expanded Big Data & AI World and country pavilions that highlight local digital transformation efforts.

In addition, this will be the first year that Cyber Security World is partnering with ISACA to provide continuing professional education (CPE) points for their members, reinforcing Cyber Security World’s position as a leading platform for interdisciplinary learning and professional growth in cybersecurity. The growth of AI has also created unprecedented demand for data centre and DC solutions in Asia Pacific. Attendees can look forward to Asia’s leading data centre show – Data Centre World – that is bigger and better this year with a 75% increase in space and an expanded line-up of exhibitors.

"The quality of speakers and attending industry leaders, alongside valuable networking opportunities, primes Tech Week Singapore as a destination where innovation, education, and investment converge to empower businesses. Amid rapid technological change, this event continues to be a key platform for ecosystem players and governments to navigate Asia’s tech landscape together," said Andy Kiwanuka, Managing Director, CloserStill Media (Asia).

Tech Week Singapore 2024 is expected to attract over 25,000 senior IT leaders, with more than 500 exhibitors and over 600 speakers participating. The event will be held at Marina Bay Sands from 9–10 October 2024.

To register for free and gain access to all co-located events, business leaders and visionaries across tech sectors can visit https://www.singaporetechnologyweek.com/.

PR Newswire is the Official Press Release Distribution Partner of Tech Week Singapore 2024.

About Tech Week Singapore
Tech Week Singapore is Asia’s premier conference that brings together technology pioneers, prominent enterprises, and public officials to explore the newest technological developments and their implications for business, government, and society. Business leaders and visionaries across all technology verticals come together and attend Tech Week Singapore to learn, network, and shape their organisation’s future.

Tech Week Singapore returns 9–10 October 2024, presenting seven co-located events, encompassing Cloud Expo Asia, DevOps Live!, Cyber Security World, Data Centre World, Big Data & AI World, eCommerce Expo, and Technology for Marketing.

About CloserStill Media
CloserStill Media specialises in producing high-value, content-driven events that foster professional communities across Business Technologies, Healthcare, and Future Transport and Infrastructure sectors. CloserStill Media’s portfolio includes the acclaimed Tech Week Singapore, featuring popular events such as Cloud Expo Asia and Data Centre World Asia.

Headquartered in London with 10 global offices, CloserStill Media operates with a robust team of 700 professionals across Singapore, the U.K., USA, Germany, and Spain. The company is recognised for its industry leadership, having won more exhibition awards than any other including accolades such as Best Exhibition, Best Event Launch, and Best Brand Expansion. For more information, visit www.closerstillmedia.com.

Source : Tech Week Singapore 2024 to unveil the future of innovation with world's top tech leaders in attendance

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network